Literature DB >> 23297119

[Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].

J Gibbert1, D Müller, S Fauser, S Stock.   

Abstract

Due to demographic changes in the German population a significant rise in incident cases of age-related macular degeneration (AMD) is to be expected in the coming years. Also the corresponding increase in costs of the illness requires appropriate survey instruments to allow accurate estimations of costs. The cost diary for patients with AMD developed in this study is based on a previously established systematic review. The seven studies that were included were evaluated regarding their quality in order to then extract the listed cost items. The result is a prospective survey instrument with six different cost sectors of AMD.

Entities:  

Mesh:

Year:  2013        PMID: 23297119     DOI: 10.1007/s00347-012-2750-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  18 in total

1.  The prevalence of eye disease in nursing home and non-nursing home geriatric populations.

Authors:  J W Eichenbaum; W B Burton; G M Eichenbaum; M Mulvihill
Journal:  Arch Gerontol Geriatr       Date:  1999 May-Jun       Impact factor: 3.250

2.  [Comments on current therapeutic possibilities for neovascular age-related macula degeneration].

Authors: 
Journal:  Klin Monbl Augenheilkd       Date:  2006-04       Impact factor: 0.700

Review 3.  Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost.

Authors:  Gerd Clabaugh; Marcia M Ward
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

4.  The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration.

Authors:  Kathleen Melissa Ke
Journal:  Eur J Health Econ       Date:  2009-11-21

Review 5.  [Blindness in Germany--today and in 2030].

Authors:  C Knauer; N Pfeiffer
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

6.  The cost diary: a method to measure direct and indirect costs in cost-effectiveness research.

Authors:  M E Goossens; M P Rutten-van Mölken; J W Vlaeyen; S M van der Linden
Journal:  J Clin Epidemiol       Date:  2000-07       Impact factor: 6.437

7.  Rasch analysis reveals problems with multiplicative scoring in the macular disease quality of life questionnaire.

Authors:  Robert P Finger; Eva Fenwick; Konrad Pesudovs; Manjula Marella; Ecosse L Lamoureux; Frank G Holz
Journal:  Ophthalmology       Date:  2012-09-08       Impact factor: 12.079

8.  The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Authors:  Julia Bonastre; Claude Le Pen; Gisèle Soubrane; Gabriel Quentel
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.

Authors:  Andrew Lotery; Xiao Xu; Gergana Zlatava; Jane Loftus
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

10.  Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Authors:  Alan F Cruess; Gergana Zlateva; Xiao Xu; Gisèle Soubrane; Daniel Pauleikhoff; Andrew Lotery; Jordi Mones; Ronald Buggage; Caroline Schaefer; Tyler Knight; Thomas F Goss
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more
  2 in total

1.  [Outcomes and health services research in ophthalmology].

Authors:  C Wolfram; N Pfeiffer
Journal:  Ophthalmologe       Date:  2014-05       Impact factor: 1.059

Review 2.  [Macroeconomic costs of eye diseases].

Authors:  C Hirneiß; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2014-05       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.